{"nctId":"NCT01872611","briefTitle":"Nepafenac Once Daily for Macular Edema - Study 2","startDateStruct":{"date":"2013-06"},"conditions":["Non-Proliferative Diabetic Retinopathy","Cataract"],"count":819,"armGroups":[{"label":"Nepafenac","type":"EXPERIMENTAL","interventionNames":["Drug: Nepafenac Ophthalmic Suspension, 0.3%","Drug: Prednisolone acetate"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Vehicle","Drug: Prednisolone acetate"]}],"interventions":[{"name":"Nepafenac Ophthalmic Suspension, 0.3%","otherNames":["Test intervention"]},{"name":"Vehicle","otherNames":["Nepafenac Vehicle"]},{"name":"Prednisolone acetate","otherNames":["Omnipred™","Prednisolone acetate ophthalmic suspension"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Planned cataract extraction by phacoemulsification with implantation of a posterior chamber intraocular lens;\n* History of Type 1 or 2 diabetes and non-proliferative diabetic retinopathy (NPDR) (mild, moderate, or severe) in the study eye;\n* Best-corrected visual acuity (BCVA) of 73 letters or worse in the study eye with expectation of improvement after surgery;\n* Understand and sign an informed consent document;\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Pre-existing macular edema in the study eye;\n* History in the study eye of retinal detachment, wet age-related macular degeneration, chronic or recurrent inflammatory eye disease, or prior procedures;\n* Planned cataract surgery in the fellow eye prior to the Day 90 postoperative study visit or through study exit;\n* Planned multiple procedures for the study eye during the cataract/intraocular lens;\n* Use of exclusionary medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids, as specified in protocol.\n* Participation in any other clinical study within 30 days of the screening visit;\n* Females of childbearing potential who are breast feeding, have a positive urine pregnancy test at screening, are not willing to undergo a urine pregnancy test upon entering or exiting the study, intend to become pregnant during the study, or do not agree to use adequate birth control methods for the duration of the study;\n* Other protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90","description":"BCVA (with spectacles or other visual corrective devices) was reported in letters read correctly, using the Early Treatment Diabetic Retinopathy Study (ETDRS) test of 70 letters. Improvement of BCVA was defined as an increase (gain) in the number of letters read, compared to the baseline assessment. One eye (study eye) contributed to the analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null},{"groupId":"OG001","value":"50.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0)","description":"Macular edema was defined as ≥ 30% Increase from pre-operative baseline in central subfield macular thickness, as measured with Spectral Domain Ocular Coherence Tomography (SD-OCT). One eye (study eye) contributed to the analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 90","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.4","spread":null},{"groupId":"OG001","value":"65.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With BCVA Improvement of ≥ 15 Letters From Preoperative Baseline to Day 60","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9","spread":null},{"groupId":"OG001","value":"62.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a > 5-letter Loss in BCVA From Day 7 to Any Visit","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7","spread":null},{"groupId":"OG001","value":"16.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With With a > 10-letter Loss in BCVA From Day 7 to Any Visit","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":819},"commonTop":[]}}}